The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia.
Karen SauveAubrey WatsonJun T OhSteven SwiftXavier Vila-FarresWessam AbdelhadyYan Q XiongDario LeHouxGary WoodnuttArnold S BayerRaymond SchuchPublished in: The Journal of infectious diseases (2024)
CF-370 is the first engineered lysin described with potent broad-spectrum in vitro activity against multiple clinically relevant gram-negative pathogens, as well as potent in vivo efficacy in an animal model of severe invasive multisystem infection.